

Chronic obstructive pulmonary disease (COPD) Committee meeting

Date: 5/3/18 – 6/3/18

Location: London

Minutes: Draft

Committee members present:		
	Day 1	Day 2
Andrew Molyneux (Chair)	Present for items 1 - 6	Present for items 1 – 7
Katy Beckford	Present for items 1 – 6	Present for items 1 – 7
Lauren Hogg	Present for items 1 – 6	Present for items 1 – 7
Nick Hopkinson	Present for items 1 – 6	Present for items 1 – 7
Sarah MacFadyen	Present for items 1 – 6	Present for items 1 – 7
Karen O'Hara	Present for items 1 – 6	Present for items 1 – 7
Tony Perkins	Present for items 1 – 6	Present for items 1 – 7
Luisa Pettigrew	Present for items 1 – 4	Present for items 1 – 7
Louise Restrick	Present for items 1 - 3	Present for items 1 – 7
Ravijyot Saggu	Present for items 3 - 6	Present for items 1 – 7
Karen Sennett	Present for items 1 – 6	Present for items 1 – 7

In attendance:		
	Day 1	Day 2
Rupert Franklin - Guideline Commissioning Manager	N/A	Present for items 1 – 7
James Hall - Senior Medical Editor	Present for items 1 – 6	Present for items 1 – 7
Marie Harrisingh - Technical Analyst	Present for items 1 – 6	Present for items 1 – 7
Ben Johnson - Senior Technical Analyst (HE)	Present for items 1 – 6	Present for items 1 – 7
Yolanda Martinez - Technical Analyst	Present for items 1 - 4	N/A
Anneka Patel - Project Manager	Present for items 1 – 6	Present for items 1 – 7
Joshua Pink - Technical Adviser	Present for items 1 – 6	Present for items 1 – 7
Gabriel Rogers - Technical Adviser (HE)	Present for items 3 - 6	Present for items 1 – 7

Observing:		
None		

Committee minutes – COPD meeting 8

Apologies:	
Christopher Warburton	Committee member
Leslie Hayes	NICE – Business Analyst
Susan Spiers	NICE – Associate Director

Day 1 Monday 5th March 2018

1. Welcome and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to the eighth meeting on chronic obstructive pulmonary disease (COPD) and asked all to introduce themselves.</p> <p>The Chair informed the Committee of apologies as listed above.</p> <p>The Chair asked everyone to verbally declare any new interests arising since the last meeting. No new declarations were made</p> <p>The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>
2. Review Question - <i>In people with COPD, what factors (for example, viral infection) may cause an exacerbation?</i>
<p>Yolanda Martinez recapped the evidence for this review question which was presented at the last meeting.</p> <p>The Committee discussed the evidence presented and drafted one recommendation.</p>
3. Review question - <i>What is the clinical and cost effectiveness of prophylactic oral antibiotics for preventing exacerbations in people with stable COPD?</i>
<p>Marie Harrisingh presented the clinical evidence for this review question.</p> <p>The Committee discussed the evidence presented and drafted six recommendations and four research recommendations.</p>
4. Review question - <i>In people with stable COPD, what is the clinical and cost effectiveness of a long-acting muscarinic antagonist (LAMA) plus a LABA compared with:</i> <i>- a LAMA alone</i> <i>- a LABA alone</i> <i>- a LABA plus an inhaled corticosteroid (ICS)</i>
<p>Marie Harrisingh presented the clinical evidence for this review question. The committee discussed the evidence, but no recommendations were made at this point in time. Ben Johnson began his presentation of the novel economic model developed to address this</p>

Committee minutes – COPD meeting 8

question.

5. AOB

There was no other business.

6. Summary

The Chair thanks the Committee for their input and confirmed day 2 would commence at the earlier time of 9am.

Day 2 Tuesday 6th March 2018

1. Welcome and objectives for the day

The Chair welcomed the Committee members and attendees to second day of the eighth meeting on chronic obstructive pulmonary disease.

The Chair informed the Committee of apologies as listed.

The Chair asked everyone to verbally declare any new interests arising since the last meeting (day one). No new declarations were made. The following declaration was however marked as relevant to the discussions for this meeting:

Committee member	Declaration	Classification	Chairs action
Tony Perkins	Phone discussion with Sandoz pharmaceutical rep on Thursday 11.1.18. Discussed their product AirFluSal which is another brand of salmeterol / fluticasone inhaler, in preparation for a Devon formulary application meeting taking place on Wednesday 17.1.18	specific, personal, non-financial	Partial exclusion - declare and participate in discussions, however excluded from recommendations

2. Economic model

Ben Johnson continued his presentation of the economic model for the Committee's consideration.

3. Recommendations

The Committee discussed the clinical evidence and the economic model and drafted three

Committee minutes – COPD meeting 8

recommendations and two research recommendations.

4. Review question from a previous meeting continued – Network meta-analysis data
Which is the most clinically and cost-effective long-acting anticholinergic for managing stable COPD, and which subgroups of people should receive treatment with it?

Marie Harrisingh recapped part of this review question which was presented at a previous meeting and presented the new NMA data

5. Recommendations

The Committee discussed the evidence presented and combined the recommendation for this question with the recommendations for the previous question. Tony Perkins was then asked to leave the room due to his previously declared conflict of interest, and the committee were asked to consider if his contribution had influenced the recommendations, and no concerns were raised. Tony Perkins was asked to re-join the group.

6. AOB

There was no other business.

7. Summary

The chair thanked the Committee for attending and confirmed the date of the next meeting (see below)

Next meeting:

Tuesday 3 April, Derwent, London NICE Offices